GMAB.DK

1,654

+0.88%↑

COLO.B.DK

399.3

-0.75%↓

HLUNB.DK

43.1

+0.14%↑

ZEAL.DK

354.2

+2.79%↑

AMBUB.DK

63.1

+0.8%↑

GMAB.DK

1,654

+0.88%↑

COLO.B.DK

399.3

-0.75%↓

HLUNB.DK

43.1

+0.14%↑

ZEAL.DK

354.2

+2.79%↑

AMBUB.DK

63.1

+0.8%↑

GMAB.DK

1,654

+0.88%↑

COLO.B.DK

399.3

-0.75%↓

HLUNB.DK

43.1

+0.14%↑

ZEAL.DK

354.2

+2.79%↑

AMBUB.DK

63.1

+0.8%↑

GMAB.DK

1,654

+0.88%↑

COLO.B.DK

399.3

-0.75%↓

HLUNB.DK

43.1

+0.14%↑

ZEAL.DK

354.2

+2.79%↑

AMBUB.DK

63.1

+0.8%↑

GMAB.DK

1,654

+0.88%↑

COLO.B.DK

399.3

-0.75%↓

HLUNB.DK

43.1

+0.14%↑

ZEAL.DK

354.2

+2.79%↑

AMBUB.DK

63.1

+0.8%↑

Home・Stock List・Novo Nordisk A-S (Class B)

Novo Nordisk A-S (Class B)

Open

302.05 3.93

Buy Sell

Overview

Share price change

24h

Current

Min

290.64

Max

306

Key metrics
By Trading Economics
Income	6.9B 27B
Sales	4.2B 79B
P/E Sector Avg	12.076 49.8
EPS	6.04
Dividend yield	4.21
Profit margin	33.977
Employees	68,794
EBITDA	3.5B 37B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+9.53% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	4.21% 2.25%
Next Earnings	5 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-404B 1.3T
Previous open	298.12
Previous close	302.05

Novo Nordisk A-S (Class B) Chart

Past performance is not a reliable indicator of future results.

Related News

6 May 2026, 07:30 UTC

Earnings

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill -- Update

6 May 2026, 06:19 UTC

Earnings

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill

7 May 2026, 09:30 UTC

Earnings

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

6 May 2026, 12:36 UTC

Earnings

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

6 May 2026, 10:53 UTC

Hot Stocks

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6 May 2026, 10:12 UTC

Earnings

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

6 May 2026, 09:58 UTC

Earnings

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

6 May 2026, 09:35 UTC

Hot Stocks

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6 May 2026, 08:13 UTC

Market Talk

Earnings

Novo Nordisk Guidance Tweak Unlikely to Drive Upgrades -- Market Talk

6 May 2026, 07:43 UTC

Market Talk

Earnings

Novo Nordisk Consensus Earnings Expectations Likely to Rise -- Market Talk

6 May 2026, 07:00 UTC

Earnings

Novo Nordisk Shares Rise 5.5% After 1Q Results

6 May 2026, 06:34 UTC

Earnings

Novo Nordisk Execs Were Speaking on Media Call After 1Q Earnings

6 May 2026, 06:26 UTC

Earnings

Novo Nordisk CFO: Branded GLP-1 Market is Expanding

6 May 2026, 06:26 UTC

Earnings

Novo Nordisk CFO: Data Indicates There is a Lower Share of Compounders in The Market

6 May 2026, 06:24 UTC

Earnings

Novo Nordisk CFO: Believe We've Found a Sweet Spot in Terms of Pricing With Wegovy Pill

6 May 2026, 06:20 UTC

Earnings

Novo Nordisk CEO: Very Excited By What We See With Wegovy Pill

6 May 2026, 06:19 UTC

Earnings

Novo Nordisk CFO: So Far Competitor's Pill Hasn't Impacted Wegovy Pill Trajectory

6 May 2026, 06:13 UTC

Earnings

Novo Nordisk CEO: Continue To Try and Improve Our Pipeline Internally and Externally

6 May 2026, 06:13 UTC

Earnings

Novo Nordisk CEO: Seen Continued Interest In Our Pill Despite Competitor Entering Market

6 May 2026, 06:12 UTC

Earnings

Novo Nordisk CFO: Impact From Higher Oil Prices is Immaterial to Co

6 May 2026, 05:43 UTC

Earnings

Novo Nordisk: Total Wegovy Pill Prescriptions Since Launch Now Exceed 2M

6 May 2026, 05:42 UTC

Earnings

Novo Nordisk: Total Prescriptions For Wegovy Pill in 1Q Reached Around 1.3M

6 May 2026, 05:40 UTC

Earnings

Novo Nordisk: First Wegovy Pill Launches Outside U.S. Expected During 2H26

6 May 2026, 05:40 UTC

Earnings

Novo Nordisk 1Q Op Margin 61.6%

6 May 2026, 05:39 UTC

Earnings

Novo Nordisk 1Q Gross Margin 85.9%

6 May 2026, 05:39 UTC

Earnings

Novo Nordisk 1Q Wegovy Injectable Sales Rose 12% at CER To DKK 18.24B, Consensus Saw DKK16.85B

6 May 2026, 05:38 UTC

Earnings

Novo Nordisk 1Q Ozempic Drug Sales Fell 8% at CER To DKK27.83B, Consensus Saw DKK26.4B

6 May 2026, 05:36 UTC

Earnings

Novo Nordisk: Analysts Saw 1Q Net Profit At DKK23.3B

6 May 2026, 05:36 UTC

Earnings

Novo Nordisk 1Q Net Pft DKK48.56B

6 May 2026, 05:36 UTC

Earnings

Novo Nordisk: Analysts Saw 1Q Op Pft at DKK49.11B

Peer Comparison

Price change

Novo Nordisk A-S (Class B) Forecast

Price Target

By TipRanks

9.53% upside

12 Months Forecast

Average 1,162.73 DKK 9.53%

High 1,550 DKK

Low 720 DKK

Based on 11 Wall Street analysts offering 12 month price targets forNovo Nordisk A-S (Class B) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Novo Nordisk A-S (Class B) - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.